Literature DB >> 23280814

Complete tumor encapsulation on magnetic resonance imaging: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma.

David S Lu1, Surachate Siripongsakun, Jeong Kyong Lee, Sindy H Wei, Phillip M Cheng, Saman Sabounchi, Jong Seok Lee, Steven Raman, Myron J Tong, Ronald W Busuttil, James Sayre.   

Abstract

The aim of this study was to determine the prognostic value of complete tumor encapsulation as visualized on magnetic resonance imaging (MRI) in patients with a solitary large hepatocellular carcinoma (HCC) beyond the Milan criteria for liver transplantation (LT). Between December 2000 and March 2011, 57 patients who had a solitary HCC exceeding 5 cm in diameter at the time of initial MRI before any treatment were identified. MRI images of the patients were independently reviewed by 2 experienced readers for the presence of complete tumoral encapsulation. The medical records of the patients were reviewed for an outcome analysis. Thirty of the 57 patients had completely encapsulated HCC according to MRI. There was excellent interobserver agreement between the 2 readers for the assessment of complete encapsulation (κ=0.86). Overall survival was significantly longer for patients with completely encapsulated HCC versus patients with incompletely or nonencapsulated tumors (P<0.001), and this included a subanalysis of 33 patients who received locoregional treatment (LRT; P=0.04). The presence of complete encapsulation was a strong predictor for survival in these patients according to both univariate [hazard ratio (HR)=0.24, 95% confidence interval (CI)=0.12-0.52, P<0.001] and multivariate analyses (HR=0.25, 95% CI=0.07-0.85, P=0.03). The rates of down-staging (P<0.001) and eventual LT (P=0.02) after LRT were also significantly higher in the patients with completely encapsulated tumors. In conclusion, complete tumor encapsulation on MRI is a potentially useful predictor for favorable biology in patients with a solitary large HCC. This new imaging biomarker may have a role in treatment selection for patients whose tumors exceed the Milan criteria size limits.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23280814     DOI: 10.1002/lt.23597

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  4 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

2.  Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus.

Authors:  Tiffany C L Wong; Tan To Cheung; Kenneth S H Chok; Albert C Y Chan; Wing Chiu Dai; See Ching Chan; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2014-11-19       Impact factor: 3.647

3.  MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features.

Authors:  Alexandra Petukhova-Greenstein; Tal Zeevi; Junlin Yang; Nathan Chai; Paul DiDomenico; Yanhong Deng; Maria Ciarleglio; Stefan P Haider; Ifeyinwa Onyiuke; Rohil Malpani; MingDe Lin; Ahmet S Kucukkaya; Luzie A Gottwald; Bernhard Gebauer; Margarita Revzin; John Onofrey; Lawrence Staib; Gowthaman Gunabushanam; Tamar Taddei; Julius Chapiro
Journal:  J Vasc Interv Radiol       Date:  2022-04-20       Impact factor: 3.682

4.  Prostate cancer with a pseudocapsule at MR imaging: a marker of high grade and stage disease?

Authors:  Apurva A Bonde; Elena K Korngold; Bryan R Foster; Antonio C Westphalen; David R Pettersson; Megan L Troxell; Jeffry P Simko; Fergus V Coakley
Journal:  Clin Imaging       Date:  2016-01-21       Impact factor: 1.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.